Centre for Eye and Vision Research

What Centre for Eye and Vision Research does

Centre for Eye and Vision Research (CEVR) is an InnoHK-funded research institute established in 2020 and headquartered at Hong Kong Science Park (Pak Shek Kok, Shatin), operating as a cross-institutional collaboration between The Hong Kong Polytechnic University and the University of Waterloo. It runs three interdisciplinary research platforms — Preserving and Restoring Healthy Vision, Next Generation Therapeutics, and Advanced Optometric Technologies — staffed by a multidisciplinary team of over 100 professionals developing technologies that prevent, detect, treat, and mitigate vision loss, including earlier detection of age-related macular degeneration (AMD).

CEVR's commercial face is a portfolio of six active ventures: MimetiCore (biomimetics nanoplatform for retinal diseases), FlavoTear (baicalein-based ocular therapy platform), Viromids (redosable, low-cost gene-delivery platform for ocular therapy), ObstAR (augmented reality software for the visually impaired), Eye-on-a-Chip Device (rapid ocular drug testing, commercialized via Eyenova Biotech), and SLOPE (Structured Light Observation and Perception Evaluation device integrating quantum optics for macular health assessment). Underlying components range from psychophysical measurement methods and quantum optics to organ-on-chip microfluidics and biomimetic nanoparticles.

The institute's business model is structured around government research grants (Hong Kong SAR InnoHK initiative), industry-partner-funded collaborations, and the licensing or spin-out of IP into ventures such as Eyenova Biotech. Go-to-market is enterprise field sales of R&D outputs to industry partners, formalized through a newly appointed Assistant Scientific Director with explicit commercialization mandate. Revenue figures, pricing, and customer logos are not publicly disclosed; the institute has no named commercial customers in the available data, indicating that monetization remains at an early, grant-funded stage with selective commercial IP transfer.

Name

Centre for Eye and Vision Research

Legal name

Centre for Eye and Vision Research

Website

https://cevr.hk

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Centre for Eye and Vision Research (CEVR) is an InnoHK-funded translational research institute in Hong Kong Science Park, jointly run by The Hong Kong Polytechnic University and the University of Waterloo, developing and commercializing eye and vision health technologies through six ventures targeting AMD, ocular therapeutics, and assistive vision tools.

Ownership category

akta.pro rank

Product category

Vision Health R&D and Ophthalmology Technology

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Ophthalmic Goods (3851), Optical Instruments & Lenses (3827)

akta.pro primary industry

Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades) (HLAHAJAJ)

Keywords

• Vision health research
• Ophthalmic technology
• Retinal disease therapeutics
• Ocular diagnostics devices
• Eye care innovation

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Collaboration and Technology Commercialization: CEVR operates as a research collaboration between The Hong Kong Polytechnic University and the University of Waterloo, funded under the InnoHK initiative of the Hong Kong SAR Government. Revenue generation appears to come from commercializing research outcomes through active ventures including MimetiCore, FlavoTear, Viromids, ObstAR, Eye-on-a-Chip Device, and SLOPE.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Centre for Eye and Vision Research (CEVR) is a translational research center that develops and commercializes proprietary technologies to prevent, detect, treat, and mitigate vision loss. The center operates three research platforms (Preserving and Restoring Healthy Vision; Next Generation Therapeutics; Advanced Optometric Technologies) and commercializes outcomes through six active ventures: MimetiCore, FlavoTear, Viromids, ObstAR, Eye-on-a-Chip Device, and SLOPE.

Product overview

CEVR is a research collaboration between The Hong Kong Polytechnic University and the University of Waterloo, forming part of the Health@InnoHK cluster, dedicated to developing technologies that prevent, detect, treat, and mitigate vision loss. The organization operates three interdisciplinary research platforms: (1) Preserving and Restoring Healthy Vision, (2) Next Generation Therapeutics, and (3) Advanced Optometric Technologies. CEVR's commercialization efforts include six active ventures: MimetiCore (biomimetics nanoplatform for retinal diseases), FlavoTear (baicalein-based ocular therapy), Viromids (gene-delivery platform for ocular therapy), ObstAR (AR software for visually impaired), Eye-on-a-Chip Device (ocular drug testing), and SLOPE (macular health assessment device).

Differentiator

Problem solved

Functional benefit

Brands

• MimetiCore: Biomimetics Nanoplatform for the Treatment of Retinal Diseases
• FlavoTear
• Viromids
• ObstAR
• Eye-on-a-Chip Device
• SLOPE

Products and services

• MimetiCore Biomimetics nanoplatform developed for the treatment of retinal diseases; commercialization venture for ophthalmic therapeutic applications.
• FlavoTear Baicalein-based novel disease platform for ocular therapy; commercialization venture addressing ophthalmic disease indications.
• Viromids Redosable, low-cost gene-delivery platform designed for ocular therapy applications; commercialization venture in ophthalmic gene therapy.
• ObstAR Augmented reality (AR) software designed to aid the visually impaired; commercialization venture targeting assistive vision technology.
• Eye-on-a-Chip Device Eye-on-a-chip device developed by Eyenova Biotech (a CEVR startup) for rapid and efficient testing of ocular drugs; won gold medals at international innovation exhibitions.
• SLOPE Structured Light Observation and Perception Evaluation (SLOPE) device integrating quantum optics and vision sciences to assess macular polarization filter function, with potential for early detection of age-related macular degeneration (AMD).

Quantifiable outcome

• SLOPE device targets early detection of AMD affecting over 200 million patients worldwide
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• The Hong Kong Polytechnic UniversitycoreStrategic or Co-development PartnerCEVR is a research collaboration between The Hong Kong Polytechnic University and the University of Waterloo, forming part of the Health@InnoHK cluster. The partnership focuses on developing technologies that prevent, detect, treat, and mitigate vision loss.
• University of WaterloocoreStrategic or Co-development PartnerThe University of Waterloo collaborates with The Hong Kong Polytechnic University on the CEVR research initiative. Dr. Chau-Minh Phan relocated from the University of Waterloo to join CEVR in Hong Kong as assistant scientific director for a five-year term.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Singapore Eye Research Institute (SERI): National eye and vision research institute under Singapore's Duke-NUS and SNEC, conducting translational vision research across ophthalmology, optometry, and visual sciences. Directly comparable to CEVR as a government-funded translational vision-research platform with multiple commercialization spin-outs.
• Moorfields Eye Hospital / UCL Institute of Ophthalmology: Joint research and clinical institute in London focused on vision science and ophthalmic disease. Directly comparable to CEVR as a leading translational vision research hub producing both academic output and commercial spin-out activity.
• Brien Holden Vision Institute: Australia-based translational vision research institute focused on eye care innovation, contact lenses, and myopia control. Comparable to CEVR as a non-profit research centre commercializing vision health IP through spin-out ventures.
• LV Prasad Eye Institute: Indian not-for-profit eye-care and vision research institute combining clinical care, research, and product development. Directly comparable in mission, structure, and translational pipeline orientation.

Broad incumbents

• Wilmer Eye Institute (Johns Hopkins): Large, established US academic vision research and clinical care institution. Comparable to CEVR as a leading translational vision research body but broader in scope, with deeper clinical-trial infrastructure and longer commercialization track record.
• Heidelberg Engineering: German ophthalmic imaging and diagnostic device company with SPECTRALIS OCT and other retinal diagnostics. Comparable to CEVR's SLOPE and Eye-on-a-Chip as a leading commercial ophthalmic diagnostic and imaging-tools supplier.
• Carl Zeiss Meditec: Global medical technology company with broad ophthalmic diagnostic and surgical device portfolio. Comparable to CEVR as a dominant incumbent in ophthalmic devices that SLOPE and Eye-on-a-Chip would compete against or partner with.
• Alcon: World's largest dedicated eye-care company spanning surgical, vision care, and ophthalmic pharmaceuticals. Comparable to CEVR's full vision-loss mission as a broad incumbent that consumes or competes with CEVR-spawned technologies.

Emerging players

• Notal Vision: US-based company developing at-home AMD monitoring technology (ForeseeHome). Comparable to CEVR's SLOPE venture as a focused player in the early AMD detection market that CEVR is targeting.
• MacuLogix: Developer of the AdaptDx dark adaptation device for early AMD detection. Directly overlaps with CEVR's SLOPE venture in the early AMD functional-diagnostics category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutu.be/nbRM_BOrM98?si=vy0AMofQV4mINxp6
• Facebookfacebook.com/cevrhk
• LinkedInlinkedin.com/company/centre-for-eye-and-vision-research
• Instagraminstagram.com/cevrhk
• Xx.com/cevr_hk

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre for Eye and Vision Research